P23 Adult onset Still’s disease as a novel autoimmune complication of alemtuzumab therapy: a case report and review of alemtuzumab associated autoimmune disease

• Published in: Rheumatology (Oxford, England) Vol. 59; no. Supplement_2
• Main Authors: Narayan, Nehal, Mazibrada, Gordon, Amft, Nicole
• Format: Journal Article
• Language: English
• Published: Oxford University Press 01.04.2020

Abstract Background Alemtuzumab is a monoclonal antibody targeted to CD52, an antigen of uncertain function on T and B lymphocytes. Alemtuzumab is an established treatment for active relapsing and remitting multiple sclerosis (MS). However, autoimmune disease (AID) is being increasingly recognised a...